Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M

OKYO Stock  USD 1.04  0.03  2.97%   
About 55% of OKYO Pharma's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding OKYO Pharma Ltd suggests that some traders are interested. OKYO Pharma's investing sentiment overview a quick insight into current market opportunities from investing in OKYO Pharma Ltd. Many technical investors use OKYO Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Okyo Pharma Ltd director. Acquisition or disposition under rule 16b-3

Read at macroaxis.com
OKYO insider trading alert for acquisition or disposition of ordinary shares by Cerrone Gabriele M, Executive Chairman, on 31st of October 2023. This event was filed by Okyo Pharma Ltd with SEC on 2023-10-31. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

OKYO Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the OKYO Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

OKYO Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards OKYO Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

OKYO Pharma Fundamental Analysis

We analyze OKYO Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OKYO Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OKYO Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

OKYO Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

OKYO Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OKYO Pharma stock to make a market-neutral strategy. Peer analysis of OKYO Pharma could also be used in its relative valuation, which is a method of valuing OKYO Pharma by comparing valuation metrics with similar companies.

Peers

OKYO Pharma Related Equities

CDIOCardio Diagnostics   41.82   
0%
100.0%
SNTISenti Biosciences   18.55   
0%
44.0%
ANEBAnebulo Pharmaceuticals   7.59   
0%
18.0%
UNCYUnicycive Therapeutics   5.80   
0%
13.0%
COEPCoeptis Therapeutics   5.56   
0%
13.0%
CMNDClearmind Medicine   4.38   
0%
10.0%
VRAXVirax Biolabs   2.79   
0%
6.0%
CADLCandel Therapeutics   1.75   
4.0%
0%
QNRXQuoin Pharmaceuticals   2.50   
5.0%
0%
CVKDCadrenal Therapeutics,   3.67   
8.0%
0%
FHTXFoghorn Therapeutics   4.11   
9.0%
0%
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out OKYO Pharma Hype Analysis, OKYO Pharma Correlation and OKYO Pharma Performance.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.